The Section 340B drug pricing program is a government program, administered by the Health Resources and Services Administration, that allows qualifying hospitals and clinics that treat low-income and uninsured patients to buy certain prescription drugs at a steep discount from drug manufacturers. Drug manufacturers participate in the Section 340B drug pricing program as a condition of obtaining Medicaid coverage of their drugs. For the many drug manufacturers who want their products to reach the broadest patient population, participation in the Section 340B program is essentially mandatory. Complex Litigation & Dispute Resolution partner William Jackson, and Life Sciences and Healthcare partner Matt Wetzel and associate Heath Ingram explain more in Law360.